ESMO 2025 Highlights Webinar-ESMO 2025 Highlights Webinar Recording

Video Transcription

Video Summary

The ISLC webinar reviewed four 2025 lung cancer studies. In the phase 1b DELPHI 303 cohorts, first-line talatamab combined with chemotherapy and immunotherapy, followed by maintenance, showed manageable toxicity and encouraging results in extensive-stage small-cell lung cancer: a 71% response rate, median progression-free survival (PFS) of 10.3 months, and median overall survival not yet reached. A larger confirmatory study is underway; safe outpatient administration remains an important practical question.<br /><br />In phase 3 Harmony 6, ivonescimab plus chemotherapy improved median PFS over tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (11.1 versus 6.9 months). Overall survival was immature, and a global trial is intended to further assess the findings.<br /><br />The phase 2 MDT BRIDGE study explored perioperative durvalumab and chemotherapy for resectable or borderline-resectable disease. Most patients received definitive surgery or chemoradiotherapy, with an overall resection rate of 85.7% and no unexpected safety signals. Speakers noted the value of multidisciplinary reassessment in identifying curative-treatment options.<br /><br />Finally, phase 3 OptiTROP-Lung04 found that the TROP2 antibody-drug conjugate sacituzumab tirumotecan improved PFS and interim overall survival versus platinum chemotherapy after EGFR-TKI progression. Its results offer a promising option, though treatment sequencing and confirmation in broader populations remain important considerations.

Meta Tag

Concept Extensive-stage Small Cell Lung Cancer

Concept Advanced Squamous Non-Small Cell Lung Cancer

Concept Resected EGFR-Mutated Non-Small Cell Lung Cancer

Concept Adjuvant Chemoimmunotherapy

Concept Progression-Free Survival

Keywords

lung cancer

DELPHI 303

talatamab

small-cell lung cancer

Harmony 6

ivonescimab

MDT BRIDGE

durvalumab

sacituzumab tirumotecan

Extensive-stage Small Cell Lung Cancer

Advanced Squamous Non-Small Cell Lung Cancer

Resected EGFR-Mutated Non-Small Cell Lung Cancer

Adjuvant Chemoimmunotherapy

Progression-Free Survival